logo
Sign In
Farxiga vs. GlyxambiBerinert vs. CinryzeEmgality vs. QuliptaFarxiga vs. InvokanaFirazyr vs. SajazirGlyxambi vs. InvokanaInvokamet vs. SynjardyOpzelura vs. DupixentOrencia vs. RinvoqQulipta vs. VyeptiStelara vs. TremfyaSynjardy vs. VictozaTaltz vs. BimzelxVyepti vs. Nurtec ODTView all Comparisons
ADHD drugsAnxiety drugsAsthma drugsAtopic dermatitis drugsDepression drugsHeart failure drugsHypertension drugsLymphoma drugsOsteoarthritis drugsRheumatoid arthritis drugsRosacea drugsSchizophrenia drugsType 2 Diabetes drugsView all Indications
Bayer drugsAbbVie drugsAstraZeneca drugsEli Lilly and Company drugsGenetech drugsGlaxoSmithKline (GSK) drugsNovartis drugsPfizer drugsTakeda Pharmaceuticals drugsTeva Pharmaceuticals drugsAmgen drugsView all Manufacturers
Beta-Adrenergic BlockerAngiotensin Converting Enzyme InhibitorAngiotensin 2 Receptor BlockerCalcium Channel BlockerDiureticsHMG-CoA Reductase InhibitorProton Pump InhibitorSelective Serotonin Reuptake InhibitorNorepinephrine Reuptake InhibitorBenzodiazepinesOpioid AgonistsNonsteroidal Anti-inflammatory DrugsAntiepileptic AgentsAntipsychoticsAntihistaminesView all Classes
Wegovy®Ozempic®Mounjaro®Zepbound®Jardiance®Farxiga®Dupixent®Trulicity®Lyrica®Lipitor®Effexor®Concerta®Depakote®Trintellix®Rexulti®Rinvoq®Verzenio®Taltz®
For ProvidersRequest DemoJoin Research Panel
For BusinessHCP ChannelCommercial O/SEngageMarketplaceOneHubInsight
Tools & MorePrescribing InfoCoverageSavingsPatient ResourcesA-Z IndicationsCompare Drugs
CompanyAboutInsightsCareersContactSecurity
Legit Script Certified
Get the latest insights in your inbox
Follow us
Legit Script Certified
  • Terms and Conditions
  • Privacy Policy
  • © 2025 PrescriberPoint. All Rights Reserved.

    • Medications for Leukemia Acute Myeloid Leukemia Aml

    FiltersReset Filters
    9 results

    • daurismo

      (glasdegib)
      Pfizer Laboratories Div Pfizer Inc
      Usage: DAURISMO, in combination with low-dose cytarabine, is indicated for treating newly-diagnosed acute myeloid leukemia (AML) in adults aged 75 and older or those with comorbidities that limit the use of intensive chemotherapy.

    • idhifa

      (enasidenib mesylate)
      Celgene Corporation
      Usage: IDHIFA is indicated for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) who have an IDH2 mutation, confirmed by an FDA-approved test.

    • mylotarg

      (gemtuzumab ozogamicin)
      Wyeth Pharmaceuticals LLC, a subsidiary of Pfizer Inc.
      Usage: MYLOTARG is indicated for the treatment of newly-diagnosed CD33-positive acute myeloid leukemia (AML) in adults and pediatric patients aged 1 month and older, as well as for relapsed or refractory CD33-positive AML in adults and pediatric patients aged 2 years and older.

    • onureg

      (azacitidine)
      Celgene Corporation
      Usage: ONUREG is indicated for the continued treatment of adults with acute myeloid leukemia who have achieved first complete remission (CR) or complete remission with incomplete blood count recovery (CRi) after intensive induction chemotherapy and are unable to complete intensive curative therapy.

    • rezlidhia

      (olutasidenib)
      Rigel Pharmaceuticals, Inc.
      Usage: REZLIDHIA is indicated for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) who have a susceptible isocitrate dehydrogenase-1 (IDH1) mutation, as confirmed by an FDA-approved test.

    • vanflyta

      (QUIZARTINIB)
      Daiichi Sankyo Inc.
      Usage: VANFLYTA is indicated for the treatment of adult patients with newly diagnosed acute myeloid leukemia (AML) that is FLT3 ITD-positive. It is used in combination with chemotherapy for induction and consolidation, and as maintenance monotherapy post-consolidation. Not for use after allogeneic stem cell transplantation.

    • venclexta

      (Venetoclax)
      AbbVie Inc.
      Usage: VENCLEXTA is indicated for adults with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). It is also indicated in combination with azacitidine, decitabine, or low-dose cytarabine for treating newly diagnosed acute myeloid leukemia (AML) in patients 75 and older or with comorbidities.

    • vyxeos

      ((daunorubicin and cytarabine) liposome)
      Jazz Pharmaceuticals, Inc.
      Usage: VYXEOS is indicated for the treatment of newly-diagnosed therapy-related acute myeloid leukemia (t-AML) or acute myeloid leukemia with myelodysplasia-related changes (AML-MRC) in adults and pediatric patients aged 1 year and older.

    • xospata

      (gilteritinib)
      Astellas Pharma US, Inc.
      Usage: XOSPATA is indicated for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) harboring a FLT3 mutation, confirmed by an FDA-approved test.